Drugs / Tovorilimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07160647 | Aug 2025 → Aug 2027 expected | rectum adenocarcinoma | Sir Run Run Shaw Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tovorilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07160647 ↗ |
| Action | Inhibit | “Anti-PD-1/CTLA-4 dual immunotherapy” NCT07160647 ↗ |
| Modality | Monoclonal antibody | “Tovorilimab, a recombinant humanized monoclonal antibody” NCT07160647 ↗ |
| Route | Intravenous | “Administer via intravenous infusion” NCT07160647 ↗ |